The impact of competition law on the pharmaceutical industry
Originally broadcast on Thursday, September 20, 2012 - 15:30
It may be argued that the rigidities of competition law fail to coexist harmoniously with the innovative and regulatory nature of the pharmaceutical industry. However, the abuse of dominance case of AstraZeneca has provided a stark demonstration that the latter is firmly within the remit of the former, and that failure to comply can potentially lead to substantial financial penalties. It is vitally important, now more than ever to keep abreast of this area of law.
Our panel of expert speakers will analyse the most relevant competition law issues affecting the pharmaceutical industry, both and UK and EU level, whilst providing an indispensable economic perspective.
This webinar will cover:
• Abuse of dominance cases
o AstraZeneca – Advocate General’s opinion/potential decision
o European case law
• Market definition - approach in merger cases
• Parallel trade
• Commercialisation agreements
• IP settlements - crossover with US enforcement approaches
• IP issues
• Negotiating remedies in merger cases
• Economic perspective